Voices
Diego A. Díaz-García: Nivolumab–Ipilimumab Plus Chemotherapy Shows Longer OS in PD-L1-Negative NSCLC
Diego A. Díaz-García/X

Diego A. Díaz-García: Nivolumab–Ipilimumab Plus Chemotherapy Shows Longer OS in PD-L1-Negative NSCLC

Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X:

”PD-L1 Negative NSCLC.

In a real-world cohort of 457 patients, nivolumab + ipilimumab + chemotherapy was associated with longer OS than pembrolizumab + chemotherapy in PD-L1 TPS <1% tumors:

  • Median OS: 47.4 vs 16.6 months
  •  HR 0.50 (p=0.007)

No OS difference was observed in PD-L1 TPS ≥1%.”

Title: Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study

Authors: Yuhei Kinehara, Kinnosuke Matsumoto, Takayuki Shiroyama, Kiyohide Komuta, Motohiro Tamiya, Kazumi Nishino, Akihiro Tamiya, Tomoki Kuge, Junji Uchida, Hidekazu Suzuki, Suguru Yamamoto, Satoshi Tobita, Toshie Niki, Satoshi Tetsumoto, Osamu Morimura, Akio Osa, Toshiyuki Minami, Izumi Nagatomo, Yoshito Takeda, Takashi Kijima, Atsushi Kumano, Atsushi Kumanogoh

Read The Full Article.

 

Diego A. Díaz-García: Nivolumab–Ipilimumab Plus Chemotherapy Shows Longer OS in PD-L1-Negative NSCLC
Nivolumab Plus Ipilimumab With Chemotherapy Shows Long-Term OS Advantage in PD-L1-Negative Advanced NSCLC
Diego A. Díaz-García: Nivolumab–Ipilimumab Plus Chemotherapy Shows Longer OS in PD-L1-Negative NSCLC

Akihiro Tamiya Akio Osa Atsushi Kumano Atsushi Kumanogoh cancer Diego A. Díaz García Hidekazu Suzuki Izumi Nagatomo Junji Uchida Kazumi Nishino Kinnosuke Matsumoto Kiyohide Komuta Lung cancer Motohiro Tamiya NSCLC OncoDaily Oncology Osamu Morimura Satoshi Tetsumoto Satoshi Tobita Suguru Yamamoto Takashi Kijima Takayuki Shiroyama Tomoki Kuge Toshie Niki Toshiyuki Minami Yoshito Takeda Yuhei Kinehara